- Home
- SENEB vs TRVI Comparison
SENEB vs TRVI Comparison
Compare SENEB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- TRVI
- Stock Information
- Founded
- SENEB 1949
- TRVI 2011
- Country
- SENEB United States
- TRVI United States
- Employees
- SENEB N/A
- TRVI N/A
- Industry
- SENEB Packaged Foods
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- TRVI Health Care
- Exchange
- SENEB Nasdaq
- TRVI Nasdaq
- Market Cap
- SENEB 720.7M
- TRVI 725.7M
- IPO Year
- SENEB N/A
- TRVI 2019
- Fundamental
- Price
- SENEB $110.00
- TRVI $8.07
- Analyst Decision
- SENEB
- TRVI Strong Buy
- Analyst Count
- SENEB 0
- TRVI 9
- Target Price
- SENEB N/A
- TRVI $20.72
- AVG Volume (30 Days)
- SENEB 250.0
- TRVI 2.9M
- Earning Date
- SENEB 11-05-2025
- TRVI 11-05-2025
- Dividend Yield
- SENEB N/A
- TRVI N/A
- EPS Growth
- SENEB N/A
- TRVI N/A
- EPS
- SENEB 6.24
- TRVI N/A
- Revenue
- SENEB $1,571,618,000.00
- TRVI N/A
- Revenue This Year
- SENEB N/A
- TRVI N/A
- Revenue Next Year
- SENEB N/A
- TRVI N/A
- P/E Ratio
- SENEB $17.34
- TRVI N/A
- Revenue Growth
- SENEB 7.30
- TRVI N/A
- 52 Week Low
- SENEB $59.95
- TRVI $2.36
- 52 Week High
- SENEB $112.00
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- SENEB 61.97
- TRVI 53.13
- Support Level
- SENEB $101.00
- TRVI $6.93
- Resistance Level
- SENEB $105.90
- TRVI $9.92
- Average True Range (ATR)
- SENEB 0.25
- TRVI 0.76
- MACD
- SENEB -0.30
- TRVI 0.11
- Stochastic Oscillator
- SENEB 42.69
- TRVI 37.96
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.